BR112021023413A2 - Método para prevenir a formação de depósitos calcificados e para inativar xenoantígenos em matrizes biológicas - Google Patents

Método para prevenir a formação de depósitos calcificados e para inativar xenoantígenos em matrizes biológicas

Info

Publication number
BR112021023413A2
BR112021023413A2 BR112021023413A BR112021023413A BR112021023413A2 BR 112021023413 A2 BR112021023413 A2 BR 112021023413A2 BR 112021023413 A BR112021023413 A BR 112021023413A BR 112021023413 A BR112021023413 A BR 112021023413A BR 112021023413 A2 BR112021023413 A2 BR 112021023413A2
Authority
BR
Brazil
Prior art keywords
formation
xenoantigens
inactivate
prevent
calcified deposits
Prior art date
Application number
BR112021023413A
Other languages
English (en)
Inventor
Alessandro Gandaglia
Filippo Naso
Original Assignee
Biocompatibility Innovation Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocompatibility Innovation Srl filed Critical Biocompatibility Innovation Srl
Publication of BR112021023413A2 publication Critical patent/BR112021023413A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3625—Vascular tissue, e.g. heart valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/02—Treatment of implants to prevent calcification or mineralisation in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/20—Materials or treatment for tissue regeneration for reconstruction of the heart, e.g. heart valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Botany (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Steroid Compounds (AREA)

Abstract

método para prevenir a formação de depósitos calcificados e para inativar xenoantígenos em matrizes biológicas. a presente invenção descreve um método para prevenir a formação de depósitos calcificados em, ou dentro de, uma matriz biológica isolada compreendendo a etapa de contatar a dita matriz biológica isolada com uma solução compreendendo uma mistura de compostos fenólicos.
BR112021023413A 2019-05-22 2020-05-22 Método para prevenir a formação de depósitos calcificados e para inativar xenoantígenos em matrizes biológicas BR112021023413A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT201900007094 2019-05-22
PCT/IB2020/054885 WO2020234845A1 (en) 2019-05-22 2020-05-22 Method for preventing the formation of calcified deposits and for inactivating xenoantigens in biological matrices

Publications (1)

Publication Number Publication Date
BR112021023413A2 true BR112021023413A2 (pt) 2022-01-04

Family

ID=67734776

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021023413A BR112021023413A2 (pt) 2019-05-22 2020-05-22 Método para prevenir a formação de depósitos calcificados e para inativar xenoantígenos em matrizes biológicas

Country Status (11)

Country Link
EP (1) EP3972659A1 (pt)
JP (1) JP2022534228A (pt)
KR (1) KR20220016119A (pt)
CN (1) CN113874052A (pt)
AU (1) AU2020277763A1 (pt)
BR (1) BR112021023413A2 (pt)
CA (1) CA3138296A1 (pt)
IL (1) IL288239A (pt)
MX (1) MX2021014295A (pt)
WO (1) WO2020234845A1 (pt)
ZA (1) ZA202109172B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113984820B (zh) * 2021-08-31 2023-05-05 中南大学湘雅二医院 提升牛心包瓣膜材料抗钙化性能的试剂组合和方法
CN118105544A (zh) * 2022-11-30 2024-05-31 上海微创心通医疗科技有限公司 生物组织材料及其制备方法和应用
CN116019980A (zh) * 2022-12-30 2023-04-28 四川大学 一种功能性交联生物瓣膜及其制备方法和用途
WO2024189407A1 (en) 2023-03-14 2024-09-19 Biocompatibility Innovation S.r.l. A method for imparting antimicrobial properties to a synthetic substrate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5843099A (en) 1999-09-22 2001-04-24 Baxter International Inc. Cardiac valve and method for preparing a biological tissue
US20040153145A1 (en) * 2002-11-26 2004-08-05 Clemson University Fixation method for bioprostheses
CN100360190C (zh) * 2005-11-30 2008-01-09 中国科学院上海硅酸盐研究所 具有生物活性的人工生物瓣瓣膜的制备方法
CN101161293A (zh) * 2006-10-12 2008-04-16 胡盛寿 异种生物组织材料的抗钙化改性方法
ITPD20120029A1 (it) 2012-02-09 2013-08-10 Alessandro Gandaglia Metodo per la rilevazione di uno xenoantigene in tessuti fissati usati come sostituti bioprotesici
US9283241B2 (en) * 2012-07-10 2016-03-15 Clemson University Treatment to render implants resistant to diabetes
ITUB20156019A1 (it) * 2015-11-30 2017-05-30 Biocompatibility Innovation Soc A Responsabilita Limitata Semplificata Metodo per l'inattivazione di xenoantigeni in tessuti biologici
US11344575B2 (en) * 2016-08-15 2022-05-31 Summit Innovation Labs, LLC Vascular calcification prevention and treatment
CN107349215A (zh) * 2017-08-30 2017-11-17 江南大学 王不留行黄酮苷在制备抗血管钙化药物中的应用
CN108498869B (zh) * 2018-04-08 2020-12-25 中国医学科学院生物医学工程研究所 多酚类交联剂及其在制备抗钙化生物瓣膜中的应用

Also Published As

Publication number Publication date
CA3138296A1 (en) 2020-11-26
ZA202109172B (en) 2024-05-30
IL288239A (en) 2022-01-01
MX2021014295A (es) 2022-01-06
WO2020234845A1 (en) 2020-11-26
CN113874052A (zh) 2021-12-31
AU2020277763A1 (en) 2021-12-16
KR20220016119A (ko) 2022-02-08
EP3972659A1 (en) 2022-03-30
JP2022534228A (ja) 2022-07-28

Similar Documents

Publication Publication Date Title
BR112021023413A2 (pt) Método para prevenir a formação de depósitos calcificados e para inativar xenoantígenos em matrizes biológicas
CO2020013762A2 (es) Compuestos dirigidos a brm y métodos de uso asociados
CL2018000198A1 (es) Composiciones de arni de transtiretina (ttr) y métodos para su uso para el tratamiento o prevencion de enfermedades asociadas con ttr
CL2020002401A1 (es) Composiciones de arni de 17 b-hidroxiesteroide deshidrogenasas tipo 13 (hsd17b13) y métodos de uso de las mismas.
BR112018004620A2 (pt) moduladores da expressão de kras
CO2020015314A2 (es) Composiciones de arni contra el angiotensinógeno (agt) y métodos para su uso
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
BR112017028194A2 (pt) moduladores de diaciglicerol aciltransferase 2 (dgat2)
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
PE20160192A1 (es) Composiciones y metodo para tratar condiciones asociadas con el complemento
CO2018005393A2 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos
BR112022005711A2 (pt) Métodos e composições para tratar uma doença ou transtorno
CO2019006234A2 (es) Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal
CL2021002262A1 (es) Composiciones y métodos para tratar laminopatías
CL2022001708A1 (es) Decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
BR112018071601A2 (pt) métodos, composições e usos relacionados aos mesmos
BR112021020183A2 (pt) Terapias gênicas para distúrbios lisossomais
CO2019002608A2 (es) Biomarcadores de arn para angioedema hereditario
CO2024009571A2 (es) Inhibidores de parp1
BR112018071568A2 (pt) métodos, composições e usos relacionados aos mesmos
CL2021001246A1 (es) Moduladores de expresión irf5.
BR112018071618A2 (pt) métodos, composições e usos relacionados aos mesmos
BR112021018688A2 (pt) Composição para prevenir ou tratar doença cerebral e do sistema nervoso
BR112022012280A2 (pt) Combinações